Listen to Medscape InDiscussion: Bladder Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
S2 Episode 6: How to Improve the Experience of Bladder Cancer: BCAN
Dr Cheryl Lee and Diane Zipursky Quale, Co-founder and Director of the Bladder Cancer Advocacy Network, discuss successes and ongoing efforts to level the playing field for those who experience bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987109). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Bladder Cancer Advisory Network https://bcan.org/
Bladder Cancer Awareness Month 2023 https://bcan.org/bladder-cancer-awareness-month-2023/
Bladder Cancer Matters Podcast https://bcan.org/bladder-cancer-podcast/
BCAN Survivor to Survivor https://bcan.org/find-support/survivor-to-survivor/
Bladder Cancer Young Investigator Awards https://bcan.org/young-investigator-awards/
American Urological Association https://www.auanet.org/
Department of Defense Appropriations for Fiscal Year 2023 https://www.congress.gov/event/118th-congress/senate-event/LC70188/text?s=1&r=3
Bladder Cancer and Veterans: What You Need to Know https://news.va.gov/103200/bladder-cancer-and-veterans-what-you-need-to-know/#:~:text=Exposure%20risks%20for%20Veterans%3A%20Agent,chemicals%20during%20their%20military%20service.
20 Jul 2023
S2 Episode 5: Bladder Cancer SBRT: Meet Your Friendly Rad-Oncologist
Drs Cheryl Lee and Shekinah Elmore talk about how stereotactic body radiation therapy (SBRT) is being used in the treatment of oligometastatic bladder cancer — and how it's making a difference in patients' lives.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987108). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
ESTRO ACROP Guidelines for External Beam Radiotherapy of Patients With Uncomplicated Bone Metastases https://www.estro.org/About/Newsroom/Newsletter/Read-it-before-your-patients/ESTRO-ACROP-guidelines-for-external-beam-radio-(1)
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3) https://clinicaltrials.gov/ct2/show/NCT03862911
IMRT https://www.cancer.gov/publications/dictionaries/cancer-terms/def/imrt
Metastasis-directed Radiation Therapy With Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/35625979/
Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://pubmed.ncbi.nlm.nih.gov/30855374/
21 Jun 2023
S2 Episode 4: Advancing Urothelial Cancer Care: Combined Therapies
Drs Cheryl Lee and Andrea Apolo discuss combination systemic therapy strategies for urothelial carcinoma, including dose de-escalation for toxicity reduction, and how ctDNA efforts are paving the way for precision medicine with the promise of biomarkers.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987107). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Systemic Treatment for Advanced Urothelial Cancer: An Update on Recent Clinical Trials and Current Treatment Options https://pubmed.ncbi.nlm.nih.gov/32668516/
PD-L1 Assessment in Urothelial Carcinoma: A Practical Approach https://pubmed.ncbi.nlm.nih.gov/31930091/
Immune Checkpoint Inhibitors in Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/35621637/
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/33224141/
BCG-Unresponsive High-Grade Non-muscle Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://pubmed.ncbi.nlm.nih.gov/33772322/
23 May 2023
S2 Episode 3: Personalized Medicine in Bladder Cancer: Inflection Point
Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987106). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217053/
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) https://clinicaltrials.gov/ct2/show/NCT04660344
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) https://clinicaltrials.gov/ct2/show/NCT02450331
20 Apr 2023
S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up
Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/
Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14
20 Apr 2023
S2 Episode 1: Breaking Bladder Cancer Barriers: The Promise of Gene Therapy
Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (2020) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) https://clinicaltrials.gov/ct2/show/NCT02773849
Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988888/
8 Nov 2022
S1 Episode 6: Non-Muscle Invasive Bladder Cancer Innovations
Drs Cheryl Lee and Sima Porten discuss urinary biomarkers, enhanced cystoscopy, treatments on the horizon, and communication with team members from the cytopathology lab using the PARIS classification.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970416). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Paris System for Reporting Urinary Cytopathology https://paris.soc.wisc.edu/index.htm
Bladder Cancer Biomarkers: Optimal Utilization for Diagnosis and Recurrence https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/93133-bladder-cancer-biomarkers-optimal-utilization-for-diagnosis-and-recurrence-everyday-urology-full-text-article.html
Diagnostic Performance of Oncuria™, a Urinalysis Test for Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025333/
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer https://www.frontiersin.org/articles/10.3389/fimmu.2020.615091/full
6 Oct 2022
S1 Episode 5: Bladder Cancer Advances Abound, but for Which Patients?
Drs Cheryl Lee and Angela Smith discuss bladder cancer research focused on disparities in healthcare affecting women and minorities.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970415). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Bladder Cancer https://www.medscape.com/resource/bladder-cancer
Racial Disparity in Bladder Cancer: Trends in Tumor Presentation at Diagnosis https://www.auajournals.org/doi/10.1016/j.juro.2006.04.074
Sex and Racial Disparities in the Treatment and Outcomes of Muscle-Invasive Bladder Cancer https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(20)30992-4
8 Sept 2022
S1 Episode 4: Key Advances in Radiation Therapy for Bladder Cancer
Drs Cheryl Lee and Sophia Kamran discuss the exciting and evolving role of radiation therapy in treating bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970414). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440298/
Adaptive Radiation Therapy for Bladder Cancer: A Review of Adaptive Techniques Used in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968556/
Clinical Implementation of Artificial Intelligence-Driven Cone-Beam Computed Tomography-Guided Online Adaptive Radiotherapy in the Pelvic Region https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057957/
10 Aug 2022
S1 Episode 3: How Can ctDNA Testing Improve Bladder Cancer Care?
Drs Cheryl Lee and Peter Black share exciting new ways to use liquid biopsy ctDNA testing for bladder cancer diagnostics and patient monitoring.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970413). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Adjuvant Atezolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma (Imvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495594/
ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma https://www.nature.com/articles/s41586-021-03642-9
ClinicalTrials.gov: Treatment of Metastatic Bladder Cancer at the Time of Biochemical reLApse Following Radical Cystectomy (TOMBOLA) https://clinicaltrials.gov/ct2/show/NCT04138628
6 Jul 2022
S1 Episode 2: How to Optimize Treatment Timing in Bladder Cancer
Drs Cheryl Lee and Matthew Galsky superbly synthesize the latest critical elements for sequencing perioperative bladder cancer therapies.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970412). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Multimodal Management of Muscle Invasive Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190161/
Role of Immunotherapy in Localized Muscle Invasive Urothelial Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461126/
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795541/
6 Jul 2022
S1 Episode 1: Bladder Cancer Choices: Robotic or Open Cystectomy?
Bladder cancer surgeons, Drs Cheryl Lee and Khurshid Guru are inspired by a recent Swedish study and discuss aggregate surgical outcomes data comparing their different surgical approaches.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970411). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Guidelines for Perioperative Care After Radical Cystectomy for Bladder Cancer: Enhanced Recovery After Surgery (ERAS®) Society Recommendations https://www.clinicalnutritionjournal.com/article/S0261-5614(13)00254-9/fulltext
Association Between Smoking and Risk of Bladder Cancer Among Men and Women https://jamanetwork.com/journals/jama/fullarticle/1104233/
Robotics in Urology: No More Shadows? https://www.mdpi.com/2673-4397/1/4/28/htm/
Prognostic Impact of Comorbidity in Patients With Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262100/
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
3.0 / 5
2 ratings
Contact Medscape InDiscussion: Bladder Cancer
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Medscape InDiscussion: Bladder Cancer?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
